Physician profile
Tito Razdan
NPI 1194724948
$11,501.34
in general payments reported to CMS, 2019-2025
57 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,669 · 2020: $1,756 · 2021: $1,941 · 2022: $2,002 · 2023: $1,509 · 2024: $1,434 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,133.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,909.67 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,461.41 | 2019-2025 | |
| Pfizer INC. | $847.43 | 2019-2025 | |
| Lilly USA, LLC | $544.92 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $404.43 | 2019-2024 | Capvaxive |
| Astrazeneca Pharmaceuticals Lp | $393.69 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $388.22 | 2019-2022 | |
| Glaxosmithkline, LLC. | $385.42 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $382.73 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $371.98 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.23 | 2019-2025 | Jardiance, Ofev |
| Amarin Pharma, INC. | $325.29 | 2019-2022 | |
| Astellas Pharma US INC | $279.05 | 2019-2023 | Veozah |
| Amgen INC. | $243.09 | 2019-2025 | Prolia, Evenity, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $237.93 | 2019-2025 | Trintellix |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tito Razdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.